Key result
Peripheral artery disease was associated with higher apoB (MD 12.5 mg/dL; 95% CI 2.14-22.87) and lower apoA-I levels compared with non-PAD controls.
Why the study?
Lower limb peripheral artery disease is a leading cause of ASCVD, but data regarding the association between apolipoproteins and PAD have been discordant.
Are apolipoprotein levels (apoB, apoA-I, apoB/apoA-I ratio) associated with peripheral artery disease?
Meta-Analysis
Are apolipoprotein levels (apoB, apoA-I, apoB/apoA-I ratio) associated with peripheral artery disease?
Mean Difference: 12.5 (95% CI 2.14–22.87)
Subjects with peripheral artery disease have an atherogenic apolipoprotein profile characterized by higher apoB and lower apoA-I levels compared to controls.
Elevated apoB and apoB/apoA-I ratio associate with PAD; leaves open whether apolipoproteins refine ASCVD risk stratification beyond LDL-C.
AIMS: Lower limb peripheral artery disease (PAD) is a leading cause of atherosclerotic cardiovascular disease (ASCVD). Discordant data are available on the association between apolipoprotein and PAD. We performed a meta-analyses on the association between apolipoprotein (apo)B, apoA-I, and apoB/apoA-I ratio with PAD. METHODS AND RESULTS: PubMed, Web of Science, Scopus databases were systematically searched. Studies providing data about apoB, apoA-I, apoB/apoA-I ratio in PAD subjects and non-PAD controls were included. Differences between PAD and non-PAD subjects were expressed as mean difference (MD) with pertinent 95% confidence intervals (95%CI). Twenty-two studies were included. Peripheral artery disease subjects showed higher apoB (MD: 12.5 mg/dL, 95%CI: 2.14, 22.87) and lower apoA-I levels (MD: -7.11 mg/dL, 95%CI: -11.94, -2.28) than non-PAD controls. Accordingly, ApoB/ApoA-I ratio resulted higher in PAD subjects than non-PAD controls (MD: 0.11, 95% CI: 0.00, 0.21). Non-HDL-C showed a direct association with the difference in apoB (z-value: 4.72, P < 0.001) and an inverse association with the difference of apoA-I (z-value: -2.43, P = 0.015) between PAD subjects and non-PAD controls. An increasing BMI was associated with an increasing difference in apoA-I values between PAD subjects and non-PAD controls (z-value: 1.98, P = 0.047). CONCLUSIONS: Our meta-analysis suggests that PAD subjects exhibit increased apoB and reduced apoA-I levels, accompanied by an increased apoB/apoA-I ratio as compared with non-PAD controls.
No takes yet. Share an insight, caveat, or question.
Forte et al. (2020) conducted a meta-analysis in Peripheral arterial disease. Peripheral artery disease vs. Non-PAD controls was evaluated on apoB levels (MD 12.5, 95% CI 2.14, 22.87). Peripheral artery disease was associated with higher apoB (MD 12.5 mg/dL; 95% CI 2.14-22.87) and lower apoA-I levels compared with non-PAD controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: